Search results for "Corticoids"

showing 10 items of 165 documents

In vivo optical coherence tomography imaging in a case of mucous membrane pemphigoid and a negative Nikolsky's sign.

2017

There is currently a growing interest in new diagnostic tools of the oral cavity and mucosa which are non-invasive, repeatable and reliable. A diagnosis of a suspected, autoimmune pathology was made regarding a 57-year-old patient with desquamative gingivitis. However, a negative Nikolsky's sign did not seem to indicate a diagnosis of mucous membrane pemphigoid neither was there any indication as to the optimum location for an incisional biopsy. As an imaging method, the use of optical coherence tomography (OCT) has enabled the obtaining of tomographic (cross-sectional) scans of tissue. Such images are acquired prior to and after verifying Nikolsky's sign, thereby enabling the clinician to …

Pathologymedicine.medical_specialtyIncisional biopsyDystoninAdministration TopicalPemphigoid Benign Mucous MembraneDermatologyDiagnostic toolsEpithelium030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineOptical coherence tomographyIn vivomedicineHumansFluorescent Antibody Technique IndirectGlucocorticoidsAutoantibodiesClobetasolIndirect immunofluorescencemedicine.diagnostic_testbusiness.industryMouth Mucosa030206 dentistryGeneral MedicineMiddle Agedmedicine.diseaseGingivitisDesquamative gingivitisoptical coherence tomography mucous membrane pemphigoid Nikolsky's signNikolsky's signMucous membrane pemphigoidFemalemedicine.symptombusinessTomography Optical CoherenceThe Journal of dermatology
researchProduct

Successful treatment of adult multisystemic Langerhans cell histiocytosis with psoralen-UV-A, prednisolone, mercaptopurine, and vinblastine.

2008

Background Langerhans cell histiocytosis (LCH) is a rare disease with a peak incidence in childhood. There is limited experience with treatment options for adult patients having multisystemic LCH involvement. We report successful treatment of a 70-year-old woman with adult onset of LCH and multisystem disease (diabetes insipidus centralis, bone marrow infiltration, and lung and skin involvement). Observations A 70-year-old woman with erythematous plaques and papules of the submammary and inguinal skin attended our outpatient clinic and was diagnosed as having LCH. Organ involvement was found in the infundibulum of the pituitary gland, associated with diabetes insipidus centralis, bone marro…

Pathologymedicine.medical_specialtyPrednisoloneDermatologyVinblastineUltraviolet therapyLangerhans cell histiocytosisBone MarrowMedicineOutpatient clinicHumansGlucocorticoidsLungHistiocyteAgedSkinPhotosensitizing Agentsbusiness.industryFicusinGeneral Medicinemedicine.diseaseMercaptopurineMagnetic Resonance ImagingHistiocytosisHistiocytosis Langerhans-CellTreatment OutcomePituitary GlandImmunologyDiabetes insipidusPrednisoloneDrug Therapy CombinationFemaleUltraviolet TherapybusinessTomography X-Ray Computedmedicine.drugFollow-Up StudiesArchives of dermatology
researchProduct

Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants

2014

Acute bronchiolitis is the leading cause of lower respiratory t ract infection and hospitalization in children less than 1y ear of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease. Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles, wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to i…

PediatricsBronchiolitis; Bronchopulmonary dysplasia; Congenital heart diseases; Immunodeficiency; Oxygen therapy; Prematurity; Prevention; Prophylaxis; Respiratory syncytial virus;ReviewRespiratory syncytial virusSeverity of Illness IndexCongenital heart diseasesSettore MED/38 - Pediatria Generale E SpecialisticaAdrenergic beta-2 Receptor AntagonistsVitamin DChildrenRespiratory distressVitaminsEnvironmental exposurePatient DischargeAnti-Bacterial AgentsBronchodilator AgentsHospitalizationSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICABronchiolitisbronchiolitisPrematuritymedicine.drugPalivizumabRespiratory Therapymedicine.medical_specialtyEpinephrineDecision MakingAntibodies Monoclonal HumanizedAntiviral AgentsIntensive Care Units NeonatalBronchiolitis Respiratory syncytial virus Prematurity Bronchopulmonary dysplasia Congenital heart diseases Immunodeficiency Oxygen therapy Prevention ProphylaxismedicineHumansImmunodeficiencyAcute bronchiolitisMedical historyConsensus DocumentIntensive care medicineGlucocorticoidsPalivizumabAsthmaSaline Solution HypertonicPrimary Health CareProphylaxisbusiness.industryNebulizers and VaporizersPreventionInfant NewbornOxygen Inhalation TherapyHumidityEnvironmental ExposureAcute bronchiolitis Consensus Documentmedicine.diseaseBronchopulmonary dysplasiaOxygen therapyHypertonic salineBronchopulmonary dysplasiaBronchiolitisbusinessItalian Journal of Pediatrics
researchProduct

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application

2020

Background:Graves’ orbitopathy (GO) is the most frequent extrathyroidal manifestation of the autoimmune Graves’ disease. GO significantly impacts quality of life and has a psycho-social morbidity. Inflammation and swelling of the orbital tissue often leads to proptosis, diplopia, and decrease of visual acuity. Due to the inflammatory background of the disease, glucocorticoids (GC) have been used as a first-line treatment for decades.Methods:PubMed and MeSH database were searched for original articles, clinical trials, reviews, and meta-analyses published between 1 January 2000 and 31 March 2020 and pertaining to both the mechanism of action and immunological effects of GC as well as to the …

Pediatricsmedicine.medical_specialtylcsh:RC648-665glucocorticoidsIntravenous methylprednisolonebusiness.industryGraves’ orbitopathyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismReviewthyroid eye diseaseDiseaselcsh:Diseases of the endocrine glands. Clinical endocrinologyintravenous methylprednisolonepharmacology immunologymechanisms of action03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Action (philosophy)030221 ophthalmology & optometrymedicinebusinessTherapeutic Advances in Endocrinology and Metabolism
researchProduct

Hypersensitivity pneumonitis : Lessons from a randomized controlled trial in children

2021

Introduction Hypersensitivity pneumonitis (HP) in children is a severe interstitial lung disease and potentially, a chronic condition, if not treated appropriately. No evidence-based guidelines are available; in particular, the role of systemic glucocorticoid therapy is unclear. Methods The aim of this randomized, double-blind, placebo-controlled, parallel-group, multi-center, phase II trial in pediatric HP was to assess the outcome of HP in children after 6 months of treatment and to compare 3 months of treatment with oral prednisolone or placebo. Results After 1.5 years and the inclusion of only four children, we terminated the study prematurely. Two of the children randomized to predniso…

Pulmonary and Respiratory MedicineAdultChronic conditionPediatricsmedicine.medical_specialtyPrednisoloneMedizinPlacebolaw.inventionFEV1/FVC ratioRandomized controlled trialDouble-Blind MethodlawMedicineHumansChildGlucocorticoidsbusiness.industryInterstitial lung diseasemedicine.diseaseClinical trialPediatrics Perinatology and Child HealthPrednisolonebusinessLung Diseases InterstitialHypersensitivity pneumonitismedicine.drugAlveolitis Extrinsic Allergic
researchProduct

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

2020

Background There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality. Methods We did a multicentre, randomised controlled trial in a network of 17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assesse…

Pulmonary and Respiratory MedicineAdultMaleARDSmedicine.medical_treatmentSeverity of Illness IndexDexamethasonelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawFraction of inspired oxygenIntensive careSeverity of illnessmedicineData monitoring committeeHumans030212 general & internal medicineGlucocorticoidsDexamethasoneAgedMechanical ventilationRespiratory Distress Syndromebusiness.industryMiddle Agedmedicine.diseaseRespiration ArtificialIntensive Care UnitsTreatment Outcome030228 respiratory systemAnesthesiaAdministration IntravenousFemalebusinessmedicine.drug
researchProduct

Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.

2011

SummaryRecommended treatment for moderate to severe asthma is the combination of an inhaled corticosteroid and a long-acting beta2-agonist. The present study was designed to evaluate the efficacy of a newly developed fixed combination of ciclesonide and formoterol in comparison to the marketed fixed combination of fluticasone and salmeterol in patients with moderate asthma.This was a phase II, multi-centre, randomized, parallel-group, double-blind, double-dummy study. After a 2-week run-in period, 160 patients with moderate asthma were randomized to a 6-week treatment with ciclesonide/formoterol 320/9 μg bid (CIC/F) or fluticasone propionate/salmeterol 250/50 μg bid (FP/S), both delivered a…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUrologyCiclesonideCiclesonideFluticasone propionatechemistry.chemical_compoundYoung AdultDouble-Blind Methodimmune system diseasesPregnenedionesForced Expiratory VolumeFormoterol FumarateGermanyAdministration InhalationmedicineHumansFixed combinationAlbuterolFormoterolAnti-Asthmatic AgentsChildGlucocorticoidsFluticasoneAgedFluticasone-Salmeterol Drug Combinationbusiness.industryrespiratory systemMiddle AgedAsthmaFluticasone-Salmeterol Drug Combinationrespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilitychemistryEthanolaminesAustriaFormoterol FumarateFemaleSalmeterolFormoterolbusinessmedicine.drugRespiratory medicine
researchProduct

Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease

2005

Current therapy for chronic obstructive pulmonary disease (COPD) fails to alter its relentless progression. This remains a significant challenge and unmet need. A recent advance is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and a long-acting beta2-agonist in COPD improves lung function and quality of life, and reduces exacerbation more effectively than either drug alone. Other improvements include the introduction of tiotropium, a once-daily anticholinergic. In advanced clinical development are other once-daily bronchodilators and combinations of anticholinergic drugs and beta2-agonists. Increased understanding of the pathogenesis of COPD has led to nove…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyExacerbationPhosphodiesterase Inhibitorsmedicine.drug_classmedia_common.quotation_subjectAnti-Inflammatory AgentsPharmacologySystemic inflammationAntioxidantsPathogenesisPulmonary Disease Chronic ObstructiveAdministration InhalationAnticholinergicmedicineHumansProtease InhibitorsIntensive care medicineGlucocorticoidsmedia_commonCOPDInhalationbusiness.industryAntibodies MonoclonalAdrenergic beta-Agonistsmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesDrug developmentQuality of LifeSmoking Cessationmedicine.symptombusinessProceedings of the American Thoracic Society
researchProduct

Advances in asthma pathophysiology: stepping forward from the Maurizio Vignola experience

2015

Maurizio Vignola was a superb and innovative researcher, who wrote seminal papers on the biology of airway epithelium in asthma. Inflammation and remodelling were the main topics of his research, mostly conducted in biopsy specimens from patients with asthma of variable severity, encompassing the entire spectrum of the disease from mild to severe asthma. His observations contributed to define the biology of asthma as we know it today, and opened the way to the personalised treatment of asthma. His group has successfully continued to investigate the biology and clinical aspects of bronchial asthma, with major interest in the clinical use of biomarkers to monitor disease activity, and in the …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVariable severityAsthma phenotypesSevere asthmaDrug ResistanceMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAdrenal Cortex HormoneDisease activityGlucocorticoidAdrenal Cortex Hormonesimmune system diseasesmedicineHumansIntensive care medicineGlucocorticoidsAsthmalcsh:RC705-779Inflammationbusiness.industrylcsh:Diseases of the respiratory systemBiomarkermedicine.diseaseAsthmarespiratory tract diseasesPhysical therapyAirway RemodelingTreatment strategybusinessBiomarkersHumanEuropean Respiratory Review
researchProduct

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis

2017

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative synthesis in order to assess real impact of ICS discontinuation in COPD patients. Methods We carried out a meta-analysis via random-effects model on the available clinical evidence to evaluate the effect of ICS discontinuation in COPD. Randomized clinical trials and observational real-life studies investigating the effects of ICS withdrawal on the risk of COPD exacerbation, lung function (forced expiratory volume in 1 s [FEV1]) and quality of life (St. George's Respiratory Questionnaire [SGRQ]) were identified by sear…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSocio-culturaleSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.invention03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoidQuality of lifeRandomized controlled triallawInhaled corticosteroidForced Expiratory VolumeAdministration InhalationmedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineGlucocorticoidsRandomized Controlled Trials as TopicRespiratory Function TestCOPDInhaled corticosteroidsbusiness.industryChronic obstructive pulmonary diseaseBiochemistry (medical)medicine.diseaseRespiratory Function TestsDiscontinuationrespiratory tract diseasesChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal030228 respiratory systemWithholding TreatmentMeta-analysisRelative riskWithdrawalQuality of LifeCorticosteroidObservational studyChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)businessHuman
researchProduct